High mobility group box protein 1 neutralization therapy in ovine bacteremia: Lessons learned from an ovine septic shock model incorporating intensive care support

Stevens,Natalie  E.; Nash,Coralie  H.; Fraser,Cara  K.; Kuchel,Tim  R.; Maiden,Matthew  J.; Chapman,Marianne  J.; Diener,Kerrilyn  R.; Hayball,John  D.

doi:10.3892/etm.2019.7961

High mobility group box protein 1 neutralization therapy in ovine bacteremia: Lessons learned from an ovine septic shock model incorporating intensive care support

Authors:
- Natalie E. Stevens
- Coralie H. Nash
- Cara K. Fraser
- Tim R. Kuchel
- Matthew J. Maiden
- Marianne J. Chapman
- Kerrilyn R. Diener
- John D. Hayball
View Affiliations

Affiliations: Experimental Therapeutics Laboratory, University of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia, Discipline of Acute Care Medicine, University of Adelaide, Adelaide, SA 5000, Australia, Preclinical, Imaging and Research Laboratories, South Australian Health and Medical Research Institute, Gilles Plain, SA 5086, Australia
Published online on: August 30, 2019 https://doi.org/10.3892/etm.2019.7961
Pages: 3271-3280
Copyright: © Stevens et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sepsis is a highly complex and often fatal syndrome which varies widely in its clinical manifestations, and therapies that target the underlying uncontrolled immune status in sepsis are needed. The failure of preclinical approaches to provide significant sepsis survival benefit in the clinic is often attributed to inappropriate animal disease models. It has been demonstrated that high mobility group box protein 1 (HMGB1) blockade can reduce inflammation, mortality and morbidity in experimental sepsis without promoting immunosuppression. Within this study, we explored the use of ovine anti‑HMGB1 antibodies in a model of ovine septic shock incorporating intensive care supports (OSSICS). Results: Septic sheep exhibited elevated levels of HMGB1 within 12 h after the induction of sepsis. In this study, sepsis was induced in six anaesthetized adult Border Leicester x Merino ewes via intravenous instillation of E. coli and sheep monitored according to intensive care unit standard protocols for 26 h, with the requirement for noradrenaline as the primary endpoint. Septic sheep exhibited a hyperdynamic circulation, renal dysfunction, deranged coagulation profile and severe metabolic acidosis. Sheep were assigned a severity of illness score, which increased over time. While a therapeutic effect of intravenous anti‑HMGB1 antibody could not be observed in this model due to limited animal numbers, a reduced bacterial dose induced a septic syndrome of much lower severity. With modifications including a reduced bacterial dose, a longer timeframe and broad spectrum antibiotics, the OSSICS model may become a robust tool for preclinical assessment of sepsis therapeutics.

View Figures

View References

1	Fink MP: Animal models of sepsis. Virulence. 5:143–153. 2014. View Article : Google Scholar : PubMed/NCBI
2	Nemzek JA, Hugunin KM and Opp MR: Modeling sepsis in the laboratory: Merging sound science with animal well-being. Comp Med. 58:120–128. 2008.PubMed/NCBI
3	Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 110:3507–3512. 2013. View Article : Google Scholar : PubMed/NCBI
4	Takao K and Miyakawa T: Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 112:1167–1172. 2014. View Article : Google Scholar : PubMed/NCBI
5	Di Giantomasso D, Morimatsu H, Bellomo R and May CN: Effect of low-dose vasopressin infusion on vital organ blood flow in the conscious normal and septic sheep. Anaesth Intensive Care. 34:427–433. 2006. View Article : Google Scholar : PubMed/NCBI
6	Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
7	Pickkers P and Kox M: Towards precision medicine for sepsis patients. Crit Care. 21:112017. View Article : Google Scholar : PubMed/NCBI
8	Fujishima S: Organ dysfunction as a new standard for defining sepsis. Inflamm Regen. 36:242016. View Article : Google Scholar : PubMed/NCBI
9	Foley SR, Solano C, Simonova G, Spanevello MM, Bird RJ, Semple JW, Jackson DE, Schibler A, Fraser JF and Fung YL: A comprehensive study of ovine haemostasis to assess suitability to model human coagulation. Thromb Res. 134:468–473. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tapia P, Soto D, Bruhn A, Alegría L, Jarufe N, Luengo C, Kattan E, Regueira T, Meissner A, Menchaca R, et al: Impairment of exogenous lactate clearance in experimental hyperdynamic septic shock is not related to total liver hypoperfusion. Crit Care. 19:1882015. View Article : Google Scholar : PubMed/NCBI
11	Murakami K, Bjertnaes LJ, Schmalstieg FC, McGuire R, Cox RA, Hawkins HK, Herndon DN, Traber LD and Traber DL: A novel animal model of sepsis after acute lung injury in sheep. Crit Care Med. 30:2083–2090. 2002. View Article : Google Scholar : PubMed/NCBI
12	Su F, Wang Z, Cai Y, Rogiers P and Vincent JL: Fluid resuscitation in severe sepsis and septic shock: Albumin, hydroxyethyl starch, gelatin or ringer's lactate-does it really make a difference? Shock. 27:520–526. 2007. View Article : Google Scholar : PubMed/NCBI
13	Fenhammar J, Rundgren M, Hultenby K, Forestier J, Taavo M Kenne E, Weitzberg E, Eriksson S, Ozenci V, Wernerson A and Frithiof R: Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep. Crit Care. 18:4882014. View Article : Google Scholar : PubMed/NCBI
14	Chapman M, Maiden M, Fraser J, Nash C, Crichton F, Sideris P and Kuchel T: An ovine intensive care model of septic shock. Criti Care. 14 (Suppl 1):P42010. View Article : Google Scholar
15	Maiden MJ, Otto S, Brealey JK, Finnis ME, Chapman MJ, Kuchel TR, Nash CH, Edwards J and Bellomo R: Structure and function of the kidney in septic shock. A prospective controlled experimental study. Am J Respir Crit Care Med. 194:692–700. 2016. View Article : Google Scholar : PubMed/NCBI
16	Maiden MJ, Chapman MJ, Torpy DJ, Kuchel TR, Clarke IJ, Nash CH, Fraser JD and Ludbrook G: Triiodothyronine administration in a model of septic shock: A randomized blinded placebo-controlled trial. Crit Care Med. 44:1153–1160. 2016. View Article : Google Scholar : PubMed/NCBI
17	Gentile LF and Moldawer LL: HMGB1 as a therapeutic target for sepsis: It's all in the timing! Expert Opin Ther Targets. 18:243–245. 2014. View Article : Google Scholar : PubMed/NCBI
18	Andersson U and Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 29:139–162. 2011. View Article : Google Scholar : PubMed/NCBI
19	Lakhan N, Stevens NE, Diener KR and Hayball JD: CoVaccine HT™ adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1. J Immunol Methods. 439:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
20	Stevens NE, Chapman MJ, Fraser CK, Kuchel TR, Hayball JD and Diener KR: Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci Rep. 7:58502017. View Article : Google Scholar : PubMed/NCBI
21	Suda K, Kitagawa Y, Ozawa S, Saikawa Y, Ueda M, Ebina M, Yamada S, Hashimoto S, Fukata S, Abraham E, et al: Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg. 30:1755–1762. 2006. View Article : Google Scholar : PubMed/NCBI
22	Fleischmann C, Thomas-Rueddel DO, Hartmann M, Hartog CS, Welte T, Heublein S, Dennler U and Reinhart K: Hospital incidence and mortality rates of sepsis. Dtsch Arztebl Int. 113:159–166. 2016.PubMed/NCBI
23	Regan JK, Kannan PS, Kemp MW, Kramer BW, Newnham JP, Jobe AH and Kallapur SG: Damage-associated molecular pattern and fetal membrane vascular injury and collagen disorganization in lipopolysaccharide-induced intra-amniotic inflammation in fetal sheep. Reprod Sci. 23:69–80. 2015. View Article : Google Scholar : PubMed/NCBI
24	Gabrielyan A, Knaak S, Gelinsky M, Arnhold S and Rösen-Wolff A: Hypoxia-conditioned media allows species-specific attraction of bone marrow stromal cells without need for recombinant proteins. BMC Vet Res. 10:562013. View Article : Google Scholar
25	Frasch MG, Szynkaruk M, Prout AP, Nygard K, Cao M, Veldhuizen R, Hammond R and Richardson BS: Decreased neuroinflammation correlates to higher vagus nerve activity fluctuations in near-term ovine fetuses: A case for the afferent cholinergic anti-inflammatory pathway? J Neuroinflammation. 13:1032016. View Article : Google Scholar : PubMed/NCBI
26	Tabrizi M, Bornstein GG and Suria H: Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 12:33–43. 2009. View Article : Google Scholar : PubMed/NCBI
27	Ito I, Fukazawa J and Yoshida M: Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem. 282:16336–16344. 2007. View Article : Google Scholar : PubMed/NCBI
28	Jain S, Gautam V and Naseem S: Acute-phase proteins: As diagnostic tool. J Pharm Bioallied Sci. 3:118–127. 2011. View Article : Google Scholar : PubMed/NCBI
29	Michel O, Nagy AM, Schroeven M, Duchateau J, Nève J, Fondu P and Sergysels R: Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med. 156:1157–1164. 1997. View Article : Google Scholar : PubMed/NCBI
30	Kreger BE, Craven DE and McCabe WR: Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med. 68:344–355. 1980. View Article : Google Scholar : PubMed/NCBI
31	Hara T, Shimizu K, Ogawa F, Yanaba K, Iwata Y, Muroi E, Takenaka M, Komura K, Hasegawa M, Fujimoto M and Sato S: Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. Am J Pathol. 176:259–269. 2009. View Article : Google Scholar : PubMed/NCBI
32	Ishikura H, Nakamura Y, Kawano Y, Tanaka J, Mizunuma M, Ohta D, Nishida T and Murai A: Intravenous immunoglobulin improves sepsis-induced coagulopathy: A retrospective, single-center observational study. J Crit Care. 30:579–583. 2015. View Article : Google Scholar : PubMed/NCBI
33	Fink MP and Warren HS: Strategies to improve drug development for sepsis. Nat Rev Drug Discov. 13:741–758. 2014. View Article : Google Scholar : PubMed/NCBI
34	Opal SM, Dellinger RP, Vincent JL, Masur H and Angus DC: The next generation of sepsis clinical trial designs: What is next after the demise of recombinant human activated protein C?*. Crit Care Med. 42:1714–1721. 2014. View Article : Google Scholar : PubMed/NCBI
35	Mebazaa A, Laterre PF, Russell JA, Bergmann A, Gattinoni L, Gayat E, Harhay MO, Hartmann O, Hein F, Kjolbye AL, et al: Designing phase 3 sepsis trials: Application of learned experiences from critical care trials in acute heart failure. J Intensive Care. 4:242016. View Article : Google Scholar : PubMed/NCBI
36	Shrum B, Anantha RV, Xu SX, Donnelly M, Haeryfar SM, McCormick JK and Mele T: A robust scoring system to evaluate sepsis severity in an animal model. BMC Res Notes. 7:2332014. View Article : Google Scholar : PubMed/NCBI
37	Sathe PM and Patwa UD: D Dimer in acute care. Int J Crit Illn Inj Sci. 4:229–232. 2014. View Article : Google Scholar : PubMed/NCBI